ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Short Interest Update

ASLAN Pharmaceuticals Limited (NASDAQ:ASLNGet Free Report) was the target of a large drop in short interest during the month of March. As of March 31st, there was short interest totalling 116,800 shares, a drop of 59.8% from the March 15th total of 290,500 shares. Approximately 0.7% of the company’s shares are short sold. Based on an average trading volume of 979,300 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ASLN shares. Piper Sandler reissued an “overweight” rating and issued a $10.00 price target (down previously from $15.00) on shares of ASLAN Pharmaceuticals in a report on Wednesday, March 13th. HC Wainwright cut their target price on shares of ASLAN Pharmaceuticals from $17.00 to $9.00 and set a “buy” rating on the stock in a research note on Monday, March 18th.

View Our Latest Analysis on ASLN

ASLAN Pharmaceuticals Stock Up 1.7 %

Shares of ASLN opened at $0.54 on Friday. The firm’s 50-day moving average price is $0.62 and its 200-day moving average price is $0.80. ASLAN Pharmaceuticals has a 1-year low of $0.39 and a 1-year high of $4.69.

Institutional Investors Weigh In On ASLAN Pharmaceuticals

A number of large investors have recently modified their holdings of ASLN. Virtu Financial LLC boosted its stake in ASLAN Pharmaceuticals by 389.6% during the fourth quarter. Virtu Financial LLC now owns 88,106 shares of the company’s stock worth $32,000 after acquiring an additional 70,109 shares in the last quarter. Renaissance Technologies LLC bought a new stake in ASLAN Pharmaceuticals during the first quarter worth about $64,000. Citigroup Inc. bought a new stake in ASLAN Pharmaceuticals during the fourth quarter worth about $104,000. Schonfeld Strategic Advisors LLC boosted its stake in ASLAN Pharmaceuticals by 68.2% during the third quarter. Schonfeld Strategic Advisors LLC now owns 91,500 shares of the company’s stock worth $172,000 after acquiring an additional 37,100 shares in the last quarter. Finally, Bank of America Corp DE boosted its stake in ASLAN Pharmaceuticals by 34.4% during the first quarter. Bank of America Corp DE now owns 259,722 shares of the company’s stock worth $233,000 after acquiring an additional 66,544 shares in the last quarter. Institutional investors own 58.82% of the company’s stock.

About ASLAN Pharmaceuticals

(Get Free Report)

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.

Featured Articles

Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.